Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioClin Therapeutics
San Leandro, CA, USAbioclintherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BioClin Therapeutics was a privately-held, clinical-stage biotechnology company developing vofatamab (B-701), a first-in-class human monoclonal antibody targeting FGFR3 for the treatment of metastatic and early stage bladder cancer. The lead program advanced through Phase 2 trials both as monotherapy and in combination with standard-of-care agents such as docetaxel and pembrolizumab. In late 2018, the company rebranded to Rainier Therapeutics ahead of planned pivotal studies.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Partnerships
No major pharma partnerships disclosed; investor syndicate included Sectoral Asset Management, Sofinnova Ventures, INKEF Capital.
Beyond the preview
Go deeper on BioClin Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioClin Therapeutics.